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Abstract
There is currently no systematic provision for chemotherapy 
of adult patients with cancer in Malawi.  Is the introduction 
of such a service now feasible in Malawi, and should an 
individual patient with potentially treatable disease be 
given chemotherapy in the absence of such a service?   The 
technical, economic and moral issues are discussed here in 
the form of a debate.
Introduction
A 36 year old HIV positive patient who has recently started 
on antiviral therapy and is currently in good general health 
Is cytotoxic chemotherapy for lymphoma currently 
feasible for patients in Malawi? A debate
Tiyanjane Clinic, Queen Elizabeth Central Hospital, Blantyre, Malawi
Department of  Haematology, College of  Medicine, Blantyre, Malawi
Corresponding author: Dr Emma Crutchlow, Tiyanjane Clinic, Queen 





Yes, when the patient has made an informed decision 
for treatment
Cancer is becoming an epidemic in the developing world2,3-
5. Cancer mortality ratios are much higher in Africa than in 
the West2. The majority of  African patients present with 
advanced disease when cure is unlikely2,5. To save lives 
cancer patients in Africa must have improved access to 
proven, cost-effective therapy, efficiently delivered2. The 
cost effectiveness of  CHOP can be demonstrated by the 
fact that the World Health Organisation (WHO) model list 
of  essential medicines, which is aimed at resource limited 
settings, includes the drugs6 which are in the CHOP regimen. 
To encourage early diagnosis of  cancer, it is essential that 
patients diagnosed with early-stage cancer have immediate 
access to treatment2. A study carried out in Zimbabwe 
demonstrated that African Zimbabweans had worse cancer 
survival rates than European Zimbabweans on account of  
differential access to cancer treatment (and not on account 
of  side effects)7.
The patient under discussion has presented early with disease 
which, without adding chemotherapy to his highly active 
antiretroviral therapy (HAART) treatment, will definitely 
kill him within months8, but with the addition of  CHOP he 
stands a 40% chance of  being cured – a chance similar to that 
of  an HIV negative NHL patient1,9-15. This patient should 
be offered CHOP, which is available, and be given it if  he 
accepts. After all, some resources have already been utilised 
to get the CHOP drugs into the hospital; and considerable 
effort has been taken to obtain a biopsy, to do histology and 
to perform staging investigations in this patient. Death looks 
different from a distance16, and in this situation the expected 
personal ethics of  care of  a doctor should be upheld by asking 
the one staring death in the face (the patient) to decide about 
treatment or no treatment issues. Apart from autonomy, 
presents with several months history of  an enlarged cervical 
lymph node.  Lymph node histology is reported as showing 
a high grade non-Hodgkin’s lymphoma (NHL), and staging 
investigations indicate that disease is localised.
In the developed world, a good prognosis patient such as this 
would be expected to do well with cytotoxic chemotherapy 
and continuing antiretroviral therapy, with a reported 5 
year survival of  47% with CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisolone) chemotherapy1.
There is no systematic provision for chemotherapy for adult 
patients in government hospitals in Malawi, but the drugs 
that constitute CHOP chemotherapy are currently in the 
pharmacy.  Should the patient be given this combination 
therapy, in the context of  our available resources and 
facilities?
other treasured health care values to be considered in this 
patient include dignity, prevention of  complications of  
disease, access, justice, cost control and equity in provision 
of  care17.
Denying a poor and helpless Malawian cancer patient access 
to available and potentially curative treatment is not a humane 
thing to do. Chances are that if  this patient had power and 
influence he would travel abroad anyway to countries like 
South Africa to get CHOP, most likely using public funds. 
This is very expensive because it must include patient and 
guardian air-tickets, hotel accommodation, allowances and 
exorbitant hospital charges for foreign patients. It is also not 
effective because chemotherapy regimens involve several 
cycles repeated at regular intervals. Patients may be sent to 
South Africa initially and then fail to go again weeks later, 
or they may go again so late that the benefits of  their initial 
cycle(s) are negated. Such practice more often than not 
proves that poverty can be expensive.
Statements like “Chemotherapy won’t work in Africa 
….because of  economics. We have to look at what we can 
do at the moment, and that is to improve palliative care”18 
are misleading19. Chemotherapy has not worked 100% in the 
West and some patients in the West endure some of  the most 
horrible side effects for the hope of  some benefit only to 
end up dying20, and yet cytotoxic chemotherapy is still used21-
23. It is ironic that we should have to justify chemotherapy for 
the treatment of  aggressive lymphoma in Africa when it was 
Dr Denis Burkitt who pioneered treatment of  aggressive 
lymphomas by experimenting on African children in 
Uganda24. Palliative care has many definitions most of  which 
include relief  of  symptoms. Relief  of  symptoms includes the 
provision of  chemotherapy when curative intent has been 
abandoned or is not realistic in NHL25. Some definitions 
equate palliative care with hospice (terminal) care. Yet other 
definitions equate palliative care with supportive care which 
can be given along side curative treatment.  Neither of  these 
two kinds of  palliative care would be applicable to this patient 
at this point in time, because his lymphoma is potentially 
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curable with drugs which are available.  Cancer management 
services are and should be progressive19. Pathologists and 
laboratory personnel can be motivated to improve the 
diagnostic workup of  cancer patients once they know that 
such patients can be offered treatment. 
Malawi has had at least one haematologist since the early 
1990s. Just as a cardiologist does not need to be a qualified 
diagnostic radiologist in order to perform an echocardiogram, 
a general surgeon does not need to be a qualified oncologist 
in order to perform mastectomy for breast cancer. Similarly, 
a (clinical) haematologist does not need to be a qualified 
oncologist in order to treat a patient with NHL. Training 
for Masters in Internal Medicine in countries within the 
African region such as Kenya, where they have hospitals 
with haematology and oncology wards and clinics under 
the department of  Internal Medicine, involves hands-on 
experience in administration of  chemotherapy to cancer 
patients. CHOP for lymphoma is generally safe to such an 
extent that it is mostly given in outpatient settings in hospitals 
in Kenya. CHOP can be toxic, and febrile neutropenia can 
occur but does not always occur. Attempts to find completely 
non-toxic ways of  treating aggressive lymphoma within 
Africa have never succeeded at eliminating possibilities of  
febrile neutropenia while maintaining acceptable cure rates26. 
It is instructive to note that HAART toxicity (including 
febrile neutropenia) can kill patients more than AIDS itself, 
and yet patients in Malawi are still offered HAART27.
Suboptimal, inferior or unproven cytotoxic chemotherapy 
may expose patients to side effects without real benefit, may 
be harmful or may create drug resistance. Giving vincristine 
alone, for example (instead of  CHOP), to the patient in 
question in the hope that this would provide some kind of  
“care” is like giving a smear positive tuberculosis patient 
ethambutol alone or giving an HIV positive patient AZT 
(which was used as monotherapy for treatment of  HIV in the 
West in the past) in the belief  that such treatment will help 
the patient. As far as cytotoxic chemotherapy is concerned, 
the same principles which apply in wealthy countries must 
apply in resource poor settings17 i.e. only standard, evidence-
based or expert panel recommended protocols should be 
administered to cancer patients or else patients should be 
entered in clinical trials.  
Against
Dr. E Crutchlow
‘Just because you can, doesn’t mean you should.’
I do not categorically disagree with offering cytotoxic 
chemotherapy for cancer in Malawi; but any service would 
need to be safe and sustainable.
In an infrastructure-poor setting, a service offering a 
combination of  strongly immunosuppressant drugs needs 
to be carefully administered, monitored and audited. 
Cytotoxic chemotherapy is a potentially dangerous tool 
even in infrastructure-rich settings and introducing it in a 
country where even basic hospital care is often not provided 
adequately, is in my view inhumane.  There are new therapies 
emerging that are more effective and less toxic but these are 
prohibitively expensive in most developing countries28.
Giving drugs to patients and not being able to safely monitor 
them or effectively deal with side effects and complications 
is not safe. Chemotherapy requires hospital infrastructures 
and technical expertise, yet most African countries lack 
the ideal framework to administer these treatments5.  The 
key concepts of  ethics in medicine are autonomy, justice, 
beneficience and non-malefience (‘do no harm’) and giving 
CHOP in our setting, is in my view not meeting the standard 
of  due care.
There is no doubt that if  the resources were available then the 
option of  chemotherapy should be open to all Malawians who 
need it. But the resources are not readily available; difficulties 
with diagnosis (long waits for lymph node biopsy); unreliable 
availability of  drugs (cyclophosphamide currently out of  date 
and limited stock, allopurinol also out of  stock); unreliable 
blood test results; limited blood transfusion services; no 
qualified oncologist; no specialist nurses and no space for a 
designated isolation room for neutropenic patients.  CHOP 
chemotherapy (cyclophosphamide, doxorubicin, vincristine, 
prednisolone) has been shown to cause febrile neutropenia 
in 21% of  those under 65 years29 and this is in a nutritionally 
robust and mostly HIV naïve American population.
Systems still need to be instigated and improved to achieve 
routine high quality care of  our patients on the wards, and 
until the relatively simple can be mastered there is little point 
and a degree of  risk in adding to the already overstretched 
resources.
Although in itself  the HIV/AIDS pandemic should not 
affect the provision of  cytotoxic chemotherapy to Malawians, 
it certainly may make their management more difficult. Our 
population here is undoubtedly different from that seen in the 
West, and administering cytotoxic chemotherapy to physically 
and psychologically fragile patients is a huge challenge. There 
are few data surrounding the administration of  chemotherapy 
to HIV +ve individuals, but is it really sensible in a country 
with a limited and erratic pharmacopoeia?
The majority of  patients with cancer in developing countries 
present late.  Palliative care is cheap, safe and is often the only 
choice left for the patient. The patients we see do not present 
early, when the chances of  a cure are highest – they present 
late and so palliative care is ‘where we are at’ for the majority 
of  Malawians.
The burden of  cancer in developing countries is growing 
but the majority is preventable30, as the populations are more 
susceptible to cancers stemming from infectious disease28 
– infection is responsible for 25% of  cancer in developing 
countries31. Therefore the priority must be to establish 
prevention and screening programmes, as well as improving 
training programmes and maintaining a cancer registry. 
This approach potentially offers the most valuable and cost 
effective intervention for reducing the cancer burden30. 
‘Do not try to do everything for everybody’ 28 – the concept of  
rationing is as important here as anywhere, especially when 
the total annual expenditure on health per capita in Malawi32 
is just US$ 64, and the average cost of  CHOP chemotherapy 
per person33 is US$3,118. 
There is indeed a need to increase awareness of  the need 
for improved cancer care in Africa in order to effect a co-
ordinated, well resourced, sustainable and safe cancer service 
in Malawi; but Malawi is not yet able to provide this, and until 
it can a cytotoxic chemotherapy programme is not morally 
justifiable.
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Commentary
Dr. T. Latham
The ability to treat and cure many patients with lymphoma 
has been one of  the success stories of  the last 50 years. 
Unarguably, it is relatively easy and inexpensive to administer 
chemotherapy drugs with the expectation that tumour 
regression will occur rapidly at least in the short term. However 
the progressive improvements in overall survival rates seen 
since the introduction of  combination chemotherapy in the 
1960s and 70s have largely been due to improvements in 
supportive care and the development of  organised cancer 
services rather than advances in chemotherapy drugs34.  It is 
uncertainty about the quality of  outcomes in the absence of  
such supportive care that leads to the difficulty in decision 
making.
 There are two parallel questions being argued here.  The easier 
question for academic debate is whether a chemotherapy 
service should be developed in Malawi given current 
resources.  Clearly the current situation where patients 
might be sent abroad at great expense or receive treatment 
according to what drugs are currently in the hospital is 
inconsistent and inefficient.  A consistent strategy for cancer care 
can be developed at local or national level however limited 
the resources, and would create a framework for gradual 
introduction of  a wider range of  treatment options and 
outcomes monitoring as resources allow.  The question of  
priorities is harder to resolve.  It would certainly be feasible 
to develop facilities to safely give well established regimens 
of  moderate intensity such as CHOP to a limited number of  
patients.  However there is a case that resources should first 
be concentrated on improving pathology and supportive care 
services which are prerequisites for giving chemotherapy 
safely and rationally.  Another alternative approach would 
be to concentrate on lower intensity regimens that could be 
administered more widely. Although less intense treatments 
may have been shown in a developed world context to 
achieve inferior remission rates, it is quite likely that the 
increase in treatment related mortality because of  poorer 
general healthcare conditions may reduce overall survival for 
the intensive treatments. Furthermore, more lives might be 
saved by giving an inferior treatment to a greater number of  
people.  There is no single correct solution to this dilemma, 
and so it is important to collect holistic outcome data which 
includes economic, quality of  life and availability indicators.
The harder dilemma for the clinician is what should be done 
for the individual patient in the absence of  such a service. 
Arguments that the patient will necessarily die without 
chemotherapy and so should be given the chance, however 
small, are difficult to refute; however the quality of  life of  
a poor-prognosis patient may be made worse with little real 
hope of  benefit.  In terms of  classical medical ethics, the 
conflict here is between the duties of  beneficence and non-
maleficence.  While cure is obviously the most beneficial 
outcome, the duty of  beneficence can and often must be 
satisfied in other ways such as relief  of  suffering.  The 
avoidance of  harm is the other side of  the equation.  Even 
with optimal supportive care, chemotherapy patients must 
often become worse before they get better. I think that 
there is a difference between suffering because of  disease 
and suffering as a result of  medical treatment side effects, 
especially for patients with little understanding of  modern 
healthcare.  Nevertheless, the probability of  a good outcome 
in a well-selected good prognosis patient, even in the absence 
of  good supportive care, may well be better than for many 
cancer patients treated with intensive treatments in the 
developed world35.   As always, the final decision remains 
one that must be taken according the conscience of  the 
individual clinician and the wishes of  the patient.
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